



# CDC Recommendation for ABRYSVO<sup>®</sup> to Help Protect Eligible Adults Age 50+ From Severe RSV



CDC recommended as a single dose for<sup>1</sup>:

All adults **75+** and **50-74** with certain risk factors for severe RSV disease<sup>\*\*</sup>

<sup>\*</sup>Patient attestation is sufficient evidence of the presence of a risk factor. Vaccinators should not deny RSV vaccination to a person because of lack of medical documentation.<sup>1</sup>

<sup>\*</sup>RSV vaccination should be given only to adults who have not yet received a dose of RSV vaccine. Providers can give the RSV vaccine year round. However, RSV vaccination will have the most benefit if given in the late summer or early fall.<sup>1</sup>



## Risk factors for severe RSV disease include<sup>1</sup>



**Chronic cardiovascular disease** (eg, heart failure, coronary artery disease, or congenital heart disease [excluding isolated hypertension])



**Chronic lung or respiratory disease** (eg, chronic obstructive pulmonary disease, emphysema, asthma, interstitial lung disease, or cystic fibrosis)



**End-stage renal disease or dependence on hemodialysis or other renal replacement therapy**



**Diabetes mellitus complicated by chronic kidney disease, neuropathy, retinopathy, or other end-organ damage, or requiring treatment with insulin or SGLT-2 inhibitor**



**Neurologic or neuromuscular conditions causing impaired airway clearance or respiratory muscle weakness** (eg, poststroke dysphagia, amyotrophic lateral sclerosis, or muscular dystrophy [excluding history of stroke without impaired airway clearance])



**Chronic liver disease** (eg, cirrhosis)



**Chronic hematologic conditions** (eg, sickle cell disease or thalassemia)



**Severe obesity** (BMI  $\geq 40$  kg/m<sup>2</sup>)



**Moderate or severe immune compromise**



**Residence in a nursing home**



**Other chronic medical conditions or risk factors that a health care provider determines would increase the risk for severe disease due to viral respiratory infection** (eg, frailty, situations in which health care providers have concern for presence of undiagnosed chronic medical conditions, or residence in a remote or rural community where transportation of patients with severe RSV disease for escalation of medical care is challenging)

### INDICATIONS

ABRYSVO is a vaccine indicated for:

- active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
- active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV

### IMPORTANT SAFETY INFORMATION

- Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
- The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with ABRYSVO
- In clinical trials with adults aged 60+, the most commonly reported ( $\geq 10\%$ ) adverse reactions were fatigue (15.7%), headache (12.9%), pain at the injection site (10.6%), and muscle pain (10.2%)
- In clinical trials with adults aged 18-59, the most commonly reported ( $\geq 10\%$ ) adverse reactions were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%)

(continued on next page)

CDC = Centers for Disease Control and Prevention; RSV = respiratory syncytial virus.

Please see [full Prescribing Information](#) for ABRYSVO.

# Help Protect Infants Against Severe RSV From Birth Through 6 Months With Maternal Vaccination



ABRYSVO® is CDC recommended for pregnant persons as a one-time dose for prevention of RSV-associated LRTI in infants aged <6 months<sup>2</sup>

- ✓ at 32 weeks and 0 days' gestation through 36 weeks and 6 days' gestation
- ✓ during September through January in most of the US\*

Scan this QR code to help estimate the potential ABRYSVO vaccination window



This digital tool will help estimate a patient's vaccine eligibility based on ABRYSVO's approved indication (32-36 weeks gestation) and the RSV seasonal guidance provided by the CDC.

## CDC's Routine Recommended Maternal Administration Schedule<sup>2\*</sup>

VACCINE	SEP	OCT	NOV	DEC	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG
<b>ABRYSVO®</b> Respiratory Syncytial Virus Vaccine (The ONLY maternal RSV vaccine approved to help protect infants)	Routine recommended					Providers should follow local guidance from February-August*						

\*In jurisdictions with RSV seasonality that differs from most of the US (Alaska, southern Florida, Guam, Hawaii, Puerto Rico, US-affiliated Pacific Islands, and US Virgin Islands), providers should follow state, local, or territorial guidance on timing of ABRYSVO.

### INDICATION

ABRYSVO is a vaccine indicated for:

- active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age

### IMPORTANT SAFETY INFORMATION (continued)

- A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
- Appropriate medical treatment must be available in case of an anaphylactic reaction
- Syncope (fainting) may occur with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
- Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
- Vaccination with ABRYSVO may not protect all recipients
- In clinical trials with pregnant individuals, the most commonly reported ( $\geq 10\%$ ) adverse reactions were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)
- In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO vs 4.3% placebo) and neonatal jaundice (7.3% ABRYSVO vs 6.9% placebo) were observed

Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

CDC = Centers for Disease Control and Prevention; LRTD = lower respiratory tract disease; LRTI = lower respiratory tract infection; RSV = respiratory syncytial virus.

Please see [full Prescribing Information for ABRYSVO](#).

1. Centers for Disease Control and Prevention. RSV vaccine guidance for adults. Accessed July 10, 2025. [https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html#cdc\\_cg\\_special\\_populations\\_risks-recommendations](https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html#cdc_cg_special_populations_risks-recommendations)  
 2. Fleming-Dutra KE, et al. *MMWR Morb Mortal Wkly Rep.* 2023;72:1115-1122.

